Christopher W. Cain - 09 Jun 2026 Form 4 Insider Report for Jade Biosciences, Inc. (JBIO)

Reporting relationship: Director
Issuer ticker: JBIO
Reported as of: 09 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2026, 16:47:04 UTC
Prior SEC filing: 25 Mar 2026
Next SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Balta, as attorney-in-fact for Christopher W. Cain

Key filing fact

Christopher W. Cain filed Form 4 for Jade Biosciences, Inc. (JBIO) on 11 Jun 2026.

Key facts

This page summarizes Christopher W. Cain's Form 4 filing for Jade Biosciences, Inc. (JBIO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Jun 2026, 16:47.

Change

Previous filing in this sequence was filed on 25 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001817733 Primary reporting owner

CAIN CHRISTOPHER W.

Relationship: Director
Address: C/O JADE BIOSCIENCES, INC., 221 CRESCENT ST., BLDG. 23, STE. 105, WALTHAM
Signature: /s/ Elizabeth Balta, as attorney-in-fact for Christopher W. Cain
Signature date: 11 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JBIO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +34,843
Change %
Price: $0.000000^*
Shares after: 34,843
Date: 09 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,843
Exercise price: $15.22
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.

Footnote F2

Under the Reporting Person's arrangement with Fairmount Funds Management LLC ("Fairmount"), the Reporting Person holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.